Quality of life of patients with chronic hepatitis C: Effect of treatments;Qualité de vie des personnes malades atteintes d'hépatite chronique C: Effet des traitements

Gastroenterologie Clinique et Biologique

Volumn 26, Issue SPEC. 2, 2002, Pages

  Couzigou, Patrice ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; INTERFERON; NALTREXONE; PAROXETINE; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ANEMIA; ARTHRALGIA; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; FATIGUE; FEVER; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; NEUROTOXICITY; QUALITY OF LIFE; TREATMENT OUTCOME; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; TIME FACTORS; VIRAL LOAD;

EID: 0036262381     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Subjectively perceived quality of life
2. A research approach to improving our quality of life
3. The problem of quality of life in medicine
4. Analyse préliminaire des propriétés psychométriques de la version française d'un questionnaire international de mesure de qualité de vie: Le MOS SF36 (version 1-1)
5. Efficacity, quality of life, safety and tolerability in patients with chronic hepatitis C treated with PEG (40 KDA)IFN α-2a (PEGASYS) or standard interferon α-2b-ribavirin (rebetron) combination therapy
6. Health related quality of life in chronic hepatitis C: Impact of disease and treatment response
7. A questionnaire to assess the generic and disease specific health outcomes of patients with chronic hepatitis C
8. Mesure de la qualité de vie chez les malades ayant une hépatite chronique virale C: Validation d'un indicateur général et d'un indicateur spécifique
9. Assessing health related quality of life in chronic hepatitis C using the sickness impact profile
10. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale
11. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection
12. The effects of interferon α-2b in combination with ribavirin on health related quality of life and work productivity
13. In the eye of the beholder: Assessment of health related quality of life
14. Methodology for measuring healthstate preferences II: Scaling methods
15. Patients based health related quality of life in different stages of chronic hepatitis C
16. Chronic hepatitis C infection causes a significant reduction in quality of life in the absence of cirrhosis
17. Reduction of health related quality of life in chronic hepatitis C and improvement with interferon therapy
18. Population based study of fatigue and psychological distress
19. Fatigue en cours de l'hépatite chronique C: Un symptôme à ne pas négliger
20. Health related quality of life in patients with chronic hepatitis C in the UK
21. Impaired health-related quality of life in chronic hepatitis C: The how but not the why
22. Sustained virologic response is associated with improved health related quality of life in relapsed chronic hepatitis C patients
23. The impact of diagnostic of hepatitis C virus on quality of life
24. Psychopathology in male and female intravenous drug users with and without HIV infection
25. Hepavir. Première ètude observationnelle d'une cohorte de malades traités par interféron alpha 2a en monothérapie, évaluation de l'asthénie et de ses répercussions sociales
26. Extrahepatic manifestations in patients with chronic hepatitis C
27. An exploration of the psychosocial impact of an iatrogenic infection of hepatitis C on a previously healthy female population
28. Decompensation of live function but not cognitive impairment is the main determinant of health related quality of life in hepatitis C
29. Clinical features of hepatitis C infected patients with persistently normal alanine transaminase levels in the southwestern United States
30. Co-morbidities and quality of life in patients with interferon refractory chronic hepatitis C
31. Depressive disorders are a major cause of functional impairment among patients with chronic hepatitis C
32. Chronic fatigue syndrome: Lack of association with hepatitis C virus infection
33. Impact of HCV coinfection on HIV related quality of life
34. Evidence for a cerebral effect of the hepatitis C virus
35. Neuropsychiatric status of 100 naive chronic hepatitis C patients ready to start interferon based treatment
36. Hepatite chronique C, fatigue et métabolisme énergétique
37. Natural history and treatment impact on fatigue in patients with chronic hepatitis C a follow up in 425 patients
38. Correlation of health related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 KDA) Interferon alfa 2a (Pegasys) compared with standard interferon alfa 2a
39. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C. A randomized trial
40. Pegylated (40 KDA) interferon alfa 2a (Pegasys) in combination with ribavirin: Efficacity and safety results from a phase III, randomized, actively controlled multicenter study
41. Randomized trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus Interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
42. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
43. Safety of combination interferon alfa 2b-ribavirin therapy in chronic hepatitis C relapsed and treatment naive patients
44. Peginterferon alfa 2a in patients with chronic hepatitis C
45. A randomized double blind trial comparing pegylated interferon alfa 2b to interferon alfa 2b as initial treatment for chronic hepatitis C
46. The impact of pegylated interferon alfa 2b on health quality of life in chronic hepatitis C patients
47. Therapy with pegylated (40 KDA) intereron alfa 2a (Pegasys) significantly enhances quality of life compared with standard interferon alfa 2a (Roferon A) in patients with chronic hepatitis C
48. Treatment with 40 KDA Peginterferon alfa 2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa 2b plus ribavirin
49. Effet de l'interféron alpha 2a pégylé (Pégasys) associé á la ribavirine dans l'hépatite chronique virale C. Etude randomisée multicentrique (résumé
50. Symptoms of chronic hepatitis C and side effects of interferon therapy
51. Adherence to therapy enhances sustained response in chronic hepatitis C patients received Peg Interferon alfa 2b plus ribavirin
52. Hepatitis C in adults and adolescents with inherited coagulation disorders in the United States results of a randomized multicentrial of combination therapy (interferon α2b + ribavirin)
53. Une expérience pilote en diabétologie clinique et en psychologie médicale: L'unité de traitement et d'enseignement pour diabétiques de l'Hôpital cantonal de Genève
54. Compliance with therapy in patients with chronic hepatitis C. Association with psychiatric symptoms, interpersonal problems and mode of acquisition
55. Paroxetine for the prevention of depression indured by high dose interferon alfa
56. Mood and cognitive side effects of interferon alpha therapy
57. Treatment of neurotoxic side effects of interferon alpha with naltrexone
58. Relief from profond fatigue associated with chronic liver disease by long term ondansetron therapy
59. Once weekly epoietin alfa increases hemoglobin and decreases ribavirin dose reductions among HCV infected patients who develop anemia on ribavirin-interferon alfa 2b therapy